Phaseline

Companies › Adcentrx Therapeutics

Adcentrx Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADRX-0405
Anti-STEAP1 antibody-drug conjugate
STEAP1Phase 1Solid TumorsDec 2026
ADRX-0706
anti-Nectin-4 antibody-drug conjugate
NECTIN4Phase 1Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06710379ADRX-0405Phase 1Solid TumorsOncologyDec 2026
NCT06036121ADRX-0706Phase 1Solid TumorsOncologyDec 2026

Targets

STEAP1 (1) NECTIN4 (1)

Companies with the same targets

BicycleTx Mabwell (Shanghai) Bioscience Aktis Oncology Tianjin ConjuStar Biologics Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.